Nektar Therapeutics Additional Paid in Capital, Common Stock
Nektar Therapeutics (NKTR) had Additional Paid in Capital, Common Stock of $4.75 billion as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-14
- 2026-06-30: Additional Paid in Capital, Common Stock $4.75B.
- 2026-03-31: Additional Paid in Capital, Common Stock $4.38B.
- 2025-12-31: Additional Paid in Capital, Common Stock $3.85B.
- 2025-09-30: Additional Paid in Capital, Common Stock $3.81B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $4.75B 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $4.38B 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $3.85B 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $3.81B 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $3.67B 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $3.66B 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $3.66B 10-K · filed 2026-03-13 | $3.66B 10-K · filed 2025-03-14 |
| 2024-09-30 | $3.65B 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $3.65B 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $3.64B 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $3.61B 10-K · filed 2025-03-14 | |
| 2023-09-30 | $3.60B 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $3.59B 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $3.58B 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $3.57B 10-K · filed 2024-03-05 | |
| 2022-09-30 | $3.56B 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $3.55B 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $3.54B 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $3.52B 10-K · filed 2023-02-28 | |
| 2021-09-30 | $3.49B 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $3.47B 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $3.43B 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $3.39B 10-K · filed 2022-03-01 | |
| 2020-09-30 | $3.36B 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $3.34B 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $3.31B 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $3.27B 10-K · filed 2021-02-26 | |
| 2019-09-30 | $3.24B 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $3.21B 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $3.18B 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $3.15B 10-K · filed 2020-02-28 | |
| 2018-09-30 | $3.12B 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $3.09B 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $2.26B 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $2.21B 10-K · filed 2019-03-01 | |
| 2017-09-30 | $2.17B 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $2.15B 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $2.13B 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $2.11B 10-K · filed 2018-03-01 | |
| 2016-09-30 | $1.91B 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $1.90B 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $1.89B 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $1.88B 10-K · filed 2017-03-01 | |
| 2015-09-30 | $1.85B 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $1.84B 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $1.83B 10-Q · filed 2015-05-01 | |
| 2014-12-31 | $1.82B 10-K · filed 2016-02-29 | |
| 2014-09-30 | $1.79B 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $1.78B 10-Q · filed 2014-08-01 | |
| 2014-03-31 | $1.77B 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $1.64B 10-K · filed 2015-02-26 | |
| 2013-09-30 | $1.64B 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $1.63B 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $1.62B 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $1.62B 10-K · filed 2014-02-27 | |
| 2012-09-30 | $1.61B 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $1.61B 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $1.60B 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $1.60B 10-K · filed 2013-03-01 | |
| 2011-09-30 | $1.59B 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $1.59B 10-Q · filed 2011-08-05 | |
| 2011-03-31 | $1.58B 10-Q · filed 2011-04-29 | |
| 2010-12-31 | $1.35B 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |